OncoMatch/Clinical Trials/NCT07010692
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Is NCT07010692 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Tirbanibulin ointment 1% and non-ablative fractional laser for keratinocyte carcinoma.
Treatment: Tirbanibulin ointment 1% · non-ablative fractional laser — The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: any prior treatment
not previously treated by another method
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Bruce Robinson, MD · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify